title: Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit.
abstract: Selective decontamination of the digestive tract (SDD) selectively eradicates aerobic Gram-negative bacteria (AGNB) by the enteral administration of oral nonabsorbable antimicrobial agents, i.e., colistin and tobramycin. We retrospectively investigated the impact of SDD, applied for 5 years as part of an infection control program for the control of an outbreak with extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae in an intensive care unit (ICU), on resistance among AGNB. Colistin MICs were determined on stored ESBL-producing K. pneumoniae isolates using the Etest. The occurrence of both tobramycin resistance among pathogens intrinsically resistant to colistin (CIR) and bacteremia caused by ESBL-producing K. pneumoniae and CIR were investigated. Of the 134 retested ESBL-producing K. pneumoniae isolates, 28 were isolated before SDD was started, and all had MICs of <1.5 mg/liter. For the remaining 106 isolated after starting SDD, MICs ranged between 0.5 and 24 mg/liter. Tobramycin-resistant CIR isolates were found sporadically before the introduction of SDD, but their prevalence increased immediately afterward. Segmented regression analysis showed a highly significant relationship between SDD and resistance to tobramycin. Five patients were identified with bacteremia caused by ESBL-producing K. pneumoniae before SDD and 9 patients thereafter. No bacteremia caused by CIR was found before SDD, but its occurrence increased to 26 after the introduction of SDD. In conclusion, colistin resistance among ESBL-producing K. pneumoniae isolates emerged rapidly after SDD. In addition, both the occurrence and the proportion of tobramycin resistance among CIR increased under the use of SDD. SDD should not be applied in outbreak settings when resistant bacteria are prevalent.
authors: Laboratory for Medical Microbiology and Public Health, Enschede, The Netherlands. t.halaby@labmicta.nl
authors: Teysir
authors: T
authors: Halaby
authors: Nashwan
authors: N
authors: Al Naiemi
authors: Jan
authors: J
authors: Kluytmans
authors: Job
authors: J
authors: van der Palen
authors: Christina M J E
authors: CM
authors: Vandenbroucke-Grauls
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology; D003091:Colistin / Q000008:administration & dosage / Q000494:pharmacology*; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D003666:Decontamination; D004196:Disease Outbreaks; D024881:Drug Resistance, Bacterial; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006801:Humans; D017053:Infection Control; D007362:Intensive Care Units; D007710:Klebsiella Infections / Q000188:drug therapy; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D012189:Retrospective Studies; D014031:Tobramycin / Q000008:administration & dosage / Q000494:pharmacology*; D001618:beta-Lactamases / Q000096:biosynthesis / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D001618:beta-Lactamases; D014031:Tobramycin; D003091:Colistin
references: J Antimicrob Chemother. 2001 Jul;48 Suppl 1:59-64
references: 11420337
references: Int J Antimicrob Agents. 2005 Jan;25(1):11-25
references: 15620821
references: Clin Microbiol Rev. 2008 Jul;21(3):449-65
references: 18625681
references: Lancet. 2001 Apr 28;357(9265):1325-8
references: 11343738
references: Clin Infect Dis. 2005 May 1;40(9):1333-41
references: 15825037
references: Ann Intern Med. 1989 Jun 1;110(11):873-81
references: 2655521
references: Clin Infect Dis. 1999 Dec;29(6):1411-8
references: 10585788
references: Antimicrob Agents Chemother. 2008 Jan;52(1):351-2
references: 17954699
references: Infect Control Hosp Epidemiol. 2012 Jan;33(1):14-9
references: 22173517
references: Infect Control Hosp Epidemiol. 2008 Oct;29(10):966-8
references: 18754738
references: J Antimicrob Chemother. 2007 Nov;60(5):1163-7
references: 17761499
references: Clin Infect Dis. 1998 Oct;27(4):834-44
references: 9798042
references: Clin Infect Dis. 2011 Aug;53(4):373-6
references: 21810751
references: Intensive Care Med. 2012 Apr;38(4):533-8
references: 22293777
references: Clin Infect Dis. 2009 Jun 15;48(12):1729-31
references: 19438398
references: J Antimicrob Chemother. 2011 Apr;66(4):946-7
references: 21393203
references: Arch Intern Med. 1998 May 25;158(10):1127-32
references: 9605785
references: Infect Control Hosp Epidemiol. 2010 Jun;31(6):620-6
references: 20370465
references: Diagn Microbiol Infect Dis. 2008 Jan;60(1):1-7
references: 17888611
references: Antimicrob Agents Chemother. 2007 Oct;51(10):3726-30
references: 17646414
references: N Engl J Med. 2009 Jan 1;360(1):20-31
references: 19118302
references: J Hosp Infect. 1991 Apr;17(4):271-8
references: 1677652
references: Int J Antimicrob Agents. 2011 Jan;37(1):67-9
references: 21074372
references: J Antimicrob Chemother. 2002 Jan;49(1):205-8
references: 11751791
references: Singapore Med J. 2006 Jul;47(7):621-4
references: 16810437
references: Antimicrob Agents Chemother. 2010 Sep;54(9):3763-9
references: 20585135